01 January 1999
Effect of probucol on plasma apolipoproteins C-III in Apo B- and non-Apo B - containing lipoproteins in patients with cardiovascular artery diseaseBarbara Millo, Barbara Torbus-Lisiecka, Zdzisława Kornacewicz-Jach, Marek Naruszewicz
Med Sci Monit 1999; 5(1): CR111-117 :: ID: 505270
The distribution of apolipoproteins C-III (apo C-III) among lipoproteins may be causatively associated with cardiovascular artery disease (CAD). The objective of this study was to evaluate the changes in plasma concentration of lipids, lipoproteins and apolipoproteins in CAD patients, qualified for coronary by-pass surgery, before and after short-time administration of probucol. 19 patients (mean 53±12 years) with angiographically confirmed cardiovascular artery disease were treated with probucol (2x500 mg/day) for 3 weeks. Patients were evaluated before and after the drug administration. Levels of total apolipoproteins C-III (apo C-III) and apo C-III in plasma devoided of apo B-containig particles (apo C-III-nonLp-B) by immunoprecipitation using specific anti-apo B antiserum, were measured by electroimmunoassay. Apo C-III concentrations in apo B-containing lipoproteins (apo-C-III-LpB) were calculated by difference between total and apo C-III-nonLpB. Almost all lipid parameters significantly decreased after probucol therapy: total cholesterol from 254.8±40.1 to 213.3±44.5 mg/dl, LDL-cholesterol from 181.5±37.0 to 141±38.9 mg/dl, HDL from 40.0±5.3 to 33.6±5.5 mg/dl, triglycerides from 153.3±35.5 to 128.0±48.1mg/dl. Total apoC-III decreased from 27.3±7.2 to 23.2±8.5 mg/l, apo C-III-nonLpB from 18.8±6.8 to 13.2±5.1 mg/l, the apo C-III ratio (apo C-III-nonLp- B/apo C-III-Lp-B) changed from 2.55±1.56 to 1.47±0.63. The relationship between apo C-III, apo C-III-non- Lp-B, apo C-III-Lp-B and triglycerides remarkably changed after probucol therapy: r=0.41 (NS) vs. r=0.80 (p<0.001); r=0.42 (NS) vs. r=0.78 (p<0.001) and r=0.04 (NS) vs. r=0.55 (p<0.05), respectively. The different relationship was observed also between apo C-III-Lp-B and HDL3-cholesterol (r = -0.45, p<0.05 vs. r =-0.07, NS) Our results confirmed that probucol influences on lipid metabolism and apo C-III is involved in this process. Probucol decreased apo C-III mainly in lipoproteins without apo B, it was possible that probucol rearranged the action of apo-C-IIILpB.
Keywords: CAD, Probucol, Apolipoprotein C-III
01 May 2023 : EditorialEditorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
Med Sci Monit 2023; 29:e940911
31 May 2023 : Review articlePrevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical ResearchA Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...
Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review articleA Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...
Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database AnalysisThe COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952